The Cohance Lifesciences Limited Warning Letter breakdown
Most QA teams treat the 15-business-day response window as the finish line. Submit on time, check the box, move on.
Cohance Lifesciences did exactly that. Their inspection ended August 12, 2025. They submitted their 483 response September 2 – inside the window. Five months later, FDA issued Warning Letter 320-26-40.
The response was on time. It was also inadequate. And FDA said so in writing.
What the Warning Letter Actually Said
The lead observation cited 21 CFR 211.192 – failure to thoroughly investigate an unexplained discrepancy or batch failure. Cohance received complaints across multiple batches for crumbling, disintegrating, pitted tablets with dust in the bottle. Their investigation closed as “Not Substantiated.” Their investigation note attributed the issue to the inherent nature of a raw material – and then noted two additional complaint investigations showing the same problem across three other batches of the same product.
The firm reopened the investigation after the 483. Revised the root cause. Submitted their response.
FDA’s conclusion: “Your response is inadequate.”
Four separate failures documented in a single paragraph of the Warning Letter. Not four new findings – four things the response failed to say.
The Problem Is Not the Observation. It Is the Response.
There is specific language that signals to the reviewer at CDER headquarters that the firm does not understand the depth of its own problem. That language is in 483 responses far more often than most QA teams realize – because nobody teaches you what FDA is actually reading for.
The Cohance letter is a textbook example. The violations are not unusual. The investigation type is not unusual. What is unusual is how clearly the Warning Letter documents exactly what the response failed to include – making it one of the more instructive enforcement letters issued in early 2026.
The full analysis of the Cohance Warning Letter – including the exact language in 483 observations that signals a Warning Letter is already being drafted, the five-part response structure, and what Cohance should have written – is available to paid subscribers of The Investigator’s Lens.
Questions about your 483 situation: devaughn@fdaid.org | fdaid.org